Sanli Pharmaceutical disclosed its earnings forecast, expecting net profit attributable to the parent for the first half of 2026 to be between 32 million yuan and 45 million yuan, a year-on-year decline of 45.82% to 61.47%. Deducted non-recurring net profit is expected to be between 26 million yuan and 37 million yuan, a year-on-year decline of 47.87% to 63.37%. The company's main business is the research, development, production, and sale of pharmaceuticals. During the reporting period, affected by factors such as the deepening of DRG/DIP medical insurance payment reforms and changes in market conditions, the overall performance of the traditional Chinese medicine segment continued to face pressure, and the company's product sales fell short of expectations, leading to a decline in profits.
Guizhou Sanli Pharmaceutical Co LtdCompany forecasts 45.82%-61.47% drop in first-half 2026 net profit due to DRG/DIP reforms and weak sales.